JP2019535723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535723A5 JP2019535723A5 JP2019526262A JP2019526262A JP2019535723A5 JP 2019535723 A5 JP2019535723 A5 JP 2019535723A5 JP 2019526262 A JP2019526262 A JP 2019526262A JP 2019526262 A JP2019526262 A JP 2019526262A JP 2019535723 A5 JP2019535723 A5 JP 2019535723A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- pharmaceutically acceptable
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 62
- 229910052799 carbon Inorganic materials 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 37
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000011780 sodium chloride Substances 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423409P | 2016-11-17 | 2016-11-17 | |
| US62/423,409 | 2016-11-17 | ||
| PCT/US2017/061895 WO2018093968A1 (en) | 2016-11-17 | 2017-11-16 | Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535723A JP2019535723A (ja) | 2019-12-12 |
| JP2019535723A5 true JP2019535723A5 (US06894165-20050517-C00155.png) | 2020-11-26 |
| JP7012082B2 JP7012082B2 (ja) | 2022-01-27 |
Family
ID=60655055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526262A Active JP7012082B2 (ja) | 2016-11-17 | 2017-11-16 | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤 |
Country Status (7)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38144A (es) | 2018-03-12 | 2019-10-31 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa |
| JP7179161B2 (ja) | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| JP2022518505A (ja) * | 2019-01-23 | 2022-03-15 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| BR112021021809A2 (pt) | 2019-04-30 | 2022-01-04 | Celgene Corp | Terapias de combinação compreendendo os inibidores de apremilast e tyk2 |
| TWI810520B (zh) | 2020-02-12 | 2023-08-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
| WO2023198199A1 (zh) * | 2022-04-15 | 2023-10-19 | 先声再明医药有限公司 | 膜缔合酪氨酸和苏氨酸激酶抑制剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199119B2 (en) * | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8389527B2 (en) * | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| PA8851101A1 (es) * | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| US10273237B2 (en) * | 2013-12-10 | 2019-04-30 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses |
| KR20180081584A (ko) | 2015-11-18 | 2018-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
-
2017
- 2017-11-16 JP JP2019526262A patent/JP7012082B2/ja active Active
- 2017-11-16 WO PCT/US2017/061895 patent/WO2018093968A1/en unknown
- 2017-11-16 CN CN201780083328.6A patent/CN110191887B/zh active Active
- 2017-11-16 EP EP17812112.5A patent/EP3541817B1/en active Active
- 2017-11-16 ES ES17812112T patent/ES2849974T3/es active Active
- 2017-11-16 US US16/461,479 patent/US11299494B2/en active Active
- 2017-11-16 KR KR1020197016792A patent/KR102611856B1/ko active IP Right Grant
